RxDoctor Payments Data

Steven Rosenberg, MD

Dermatology · West Palm Beach, FLNPI 1114909108

Payments from drug & device makers

$5,449in general payments, 2019–2025

Across 153 payments — averaging $35.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$627
  • LEO Pharma Inc.$586
  • AbbVie$502
  • Incyte Corporation$407
  • Dermavant Sciences, Inc.$349
  • Regeneron Healthcare Solutions, Inc.$333
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$5,36398%
  • Education$862%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,449 in reported general payments places this provider in the 65th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$476,140
Medicare patients
638
Services billed
4,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide11$9,173
Fluocinonide34$1,164
Alclometasone Dipropionate21$769
Metronidazole13$656
Clobetasol Propionate15$644
Ketoconazole43$605
Clindamycin Phosphate14$356
Triamcinolone Acetonide66$326
Mometasone Furoate24$315
Mupirocin43$290
Doxycycline Hyclate26$288
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$118$9,17311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,147 dermatology providers in Florida.

Other dermatology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →